FF Stock Overview
Fine Foods & Pharmaceuticals N.T.M. S.p.A. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Fine Foods & Pharmaceuticals N.T.M. S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.58 |
| 52 Week High | €9.62 |
| 52 Week Low | €7.54 |
| Beta | 0.67 |
| 1 Month Change | -6.42% |
| 3 Month Change | -7.34% |
| 1 Year Change | -12.47% |
| 3 Year Change | -49.80% |
| 5 Year Change | -35.21% |
| Change since IPO | -21.45% |
Recent News & Updates
Recent updates
Solid Earnings Reflect Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Strength As A Business
Sep 20
Is There An Opportunity With Fine Foods & Pharmaceuticals N.T.M. S.p.A.'s (BIT:FF) 40% Undervaluation?
Apr 28Estimating The Fair Value Of Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF)
Mar 20Something To Consider Before Buying Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) For The 1.1% Dividend
Feb 22A Look At Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Share Price Returns
Feb 01What You Need To Know About Fine Foods & Pharmaceuticals N.T.M. S.p.A.'s (BIT:FF) Investor Composition
Jan 14We Wouldn't Rely On Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Statutory Earnings As A Guide
Dec 28Is Fine Foods & Pharmaceuticals N.T.M (BIT:FF) Using Too Much Debt?
Dec 08Shareholder Returns
| FF | IT Life Sciences | IT Market | |
|---|---|---|---|
| 7D | -3.8% | -0.6% | -0.4% |
| 1Y | -12.5% | -3.9% | 10.8% |
Return vs Industry: FF underperformed the Italian Life Sciences industry which returned -3.9% over the past year.
Return vs Market: FF underperformed the Italian Market which returned 10.8% over the past year.
Price Volatility
| FF volatility | |
|---|---|
| FF Average Weekly Movement | 3.0% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.7% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: FF has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: FF's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 780 | Marco Francesco Eigenmann | www.finefoods.it |
Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract development and manufacturing of drugs, food supplements, and other nutraceutical products and medical devices for the pharmaceutical and nutraceutical industries. It offers pharmaceutical products, including powders, soluble, effervescent and chewable granules, filmed and effervescent tablets, fast melting/sublingual tablets, film-coated tablets, and hard gelatine capsules in various types of packaging, such as sachets, sticks, pillboxes, jars, blisters, tubes, and strips for various therapeutic areas, such as probiotics, multivitamins and minerals, immune systems, sleep and relax, gastrointestinal system, circulatory system, osteoarticular system, urinary system, women health, beauty, healthy ageing, and mental wellbeing. In addition, the company is involved in the production, marketing, research, and development of cosmetics products comprising liquid detergents for personal hygiene, hair care, skin care, bath and shower gels, shampoo and conditioners, shaping waxes, mouthwash and breath products, creams, gel and toothpaste, roll-on, stick and vapo spray deodrants, intimate cleansers, emulsions and microemulsions, gels, liquid soaps, skin care emulsions, oral hygiene, deodorants, and alcohol-based perfumery products in packaging, including coextruded and laminated tubes, aluminium tubes, special packs, lip sticks, air less, and various bottles and jars under its own and third-party brands.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. Fundamentals Summary
| FF fundamental statistics | |
|---|---|
| Market cap | €185.58m |
| Earnings (TTM) | €4.85m |
| Revenue (TTM) | €243.35m |
38.2x
P/E Ratio0.8x
P/S RatioIs FF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FF income statement (TTM) | |
|---|---|
| Revenue | €243.35m |
| Cost of Revenue | €167.55m |
| Gross Profit | €75.80m |
| Other Expenses | €70.95m |
| Earnings | €4.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 31.15% |
| Net Profit Margin | 1.99% |
| Debt/Equity Ratio | 43.2% |
How did FF perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield113%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 02:42 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fine Foods & Pharmaceuticals N.T.M. S.p.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gian Gadini | Banca Akros S.p.A. (ESN) |
| Gianmarco Bonacina | Banca Akros S.p.A. (ESN) |
| Andrea Randone | Intermonte SIM S.p.A. |